The consistent gross margin above 66% suggests that ISRG maintains pricing power despite scaling, while the operating margin expansion of nearly 900 basis points over ten quarters reflects significant operating leverage. Net margin has been volatile, dipping to 27.0% in 2025Q2 and peaking at 31.0% in 2025Q1, likely due to non-recurring items or tax effects, but the underlying trend is upward. Investors should focus on operating margin as the cleanest measure of core earning power, as it excludes the noise from tax rates and one-time gains.

The absolute ROIC and ROE levels appear low, but this is partly due to the company's massive cash pile and conservative capital structure, which depresses returns on equity and invested capital. The upward trajectory in ROIC, driven by margin expansion and improving asset turnover, suggests that the company is becoming more efficient at generating returns from its invested capital. As the asset base matures and revenue grows, these returns should continue to climb, though they remain below peers like Stryker and Boston Scientific, which have higher leverage and lower cash balances.

The CCC is exceptionally long, primarily due to DIO of 194 days, which reflects the capital-intensive nature of manufacturing surgical robots and the need to hold significant inventory. DSO has improved from 61 days in 2024Q1 to 53 days in 2026Q2, indicating better receivables management, but DPO remains low at around 30 days, suggesting limited supplier leverage. The high inventory levels may be strategic to ensure supply chain resilience, but they tie up cash and could become a drag if demand softens. Asset turnover is low at 0.14, consistent with a heavy asset base, but it has been stable, indicating that revenue growth is matching asset growth.

The company operates with virtually no debt, which is unusual for a capital-intensive manufacturer and provides exceptional financial flexibility. This conservative leverage allows ISRG to invest heavily in R&D and capacity expansion without the burden of interest payments, and it positions the company to weather economic downturns or pursue opportunistic acquisitions. The absence of debt also means that the company's earnings are not levered, so the low ROE is a function of the capital structure rather than operational weakness. Investors should monitor whether the company begins to employ leverage to enhance returns, but the current stance suggests a risk-averse approach.

The current ratio has remained above 4.0 for the past ten quarters, reflecting a substantial cash and investment portfolio that far exceeds current liabilities. The quick ratio, which excludes inventory, is still above 3.9, suggesting that even without selling inventory, the company can meet its obligations. This liquidity cushion provides a buffer against operational disruptions or market volatility, and it supports the company's ability to fund its growth initiatives without external financing. However, the large cash balance also drags on returns, as it earns minimal interest, so investors should weigh the opportunity cost of this conservatism.